Record Details

Male-mediated dominant lethal mutations in mice following prooxidant treatment

IR@CSIR-CFTRI

View Archive Info
 
 
Field Value
 
Relation http://ir.cftri.com/1249/
MR-01-99
 
Title Male-mediated dominant lethal mutations in mice following
prooxidant treatment
 
Creator Rajesh Kumar, Thimappa
Muralidhara, N.
 
Subject 09 Human Physiology
17 Toxicology
 
Description This study’s primary aim is to examine if prooxidant treatment has the propensity to induce dominant lethal DL type mutations in a randomly bred closed colony of CFT-Swiss mice. Initially, graded doses of both organic hydroperoxides viz.,t-butyl hydroperoxide tbHP , and cumene hydroperoxide cHP were administered i.p. to adult males and the mortality data was analysed to determine the LD values. cHP was relatively more toxic compared to tbHP. The computed LD50 values were 1500 and 3000 mmol kg body weight for cHP and tbHP, respectively. Subsequently, adult males were administered with LD doses of hydroperoxide HP tbHP — 30 mmol 100 g body weight and cHP — 15 50 mmol 100 g body weight on 5 consecutive days and were mated with virgin females for a period of 5 weeks to characterise the male-mediated DL mutations. Male-based analysis of the three major variables viz., implantations, live embryos and dead implants DI were carried out to assess the DL-type response induction. While tbHP induced significant
increases 2- to 5-fold in the incidence of DI during the first 4 weeks, cHP induced a marginal increase only during the first week. These results suggest that prooxidants induce DL-type effect only in specific post-meiotic stages of spermatogenesis and stress the need to further investigate the implications of chronic oxidative stress on the male reproductive system.
 
Date 1999
 
Type Article
PeerReviewed
 
Format application/pdf
 
Language en
 
Rights —
 
Identifier http://ir.cftri.com/1249/1/Mutation_Research_444_1999_145-149.pdf
Rajesh Kumar, Thimappa and Muralidhara, N. (1999) Male-mediated dominant lethal mutations in mice following prooxidant treatment. Mutation Research, 444. pp. 145-149.